Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis.

Autor:	Taliento C; Department of Medical Sciences, Obstetrics and Gynecology Unit, 'S. Anna' University Hospital, University of Ferrara, Ferrara, Italy.; Department of Development and Regeneration, KU Leuven, Leuven, Belgium., Morciano G; Department of Medical Sciences, Section of Experimental Medicine and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy., Nero C; Department of Women and Child Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.; Università Cattolica del Sacro Cuore Dipartimento Scienze della Vita e Sanità Pubblica, Rome, Italy., Froyman W; Department of Development and Regeneration, KU Leuven, Leuven, Belgium.; Department of Obstetrics and Gynecology, University Hospitals KU Leuven, Leuven, Belgium., Vizzielli G; Department of Obstetrics and Gynecology, University of Udine Medical Area Department, Udine, Italy., Pavone M; Department of Women and Child Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.; IHU Strasbourg, Institute of Image Guided Surgery, Strasbourg, France., Salvioli S; Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy., Tormen M; Department of Medical Sciences, Obstetrics and Gynecology Unit, 'S. Anna' University Hospital, University of Ferrara, Ferrara, Italy., Fiorica F; Azienda ULSS 9 Scaligera, Verona, Veneto, Italy., Scutiero G; Department of Medical Sciences, Obstetrics and Gynecology Unit, 'S. Anna' University Hospital, University of Ferrara, Ferrara, Italy., Scambia G; Department of Women and Child Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Giorgi C; Department of Medical Sciences, Section of Experimental Medicine and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy., Greco P; Department of Medical Sciences, Obstetrics and Gynecology Unit, 'S. Anna' University Hospital, University of Ferrara, Ferrara, Italy., Pinton P; Department of Medical Sciences, Section of Experimental Medicine and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy paolo.pinton@unife.it.
Jazyk:	angličtina
Zdroj:	International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Jun 03; Vol. 34 (6), pp. 906-918. Date of Electronic Publication: 2024 Jun 03.
DOI:	10.1136/ijgc-2024-005313
Abstrakt:	Objectives: Circulating tumor DNA (ctDNA) is emerging as a potential prognostic biomarker in multiple tumor types. However, despite the many studies available on small series of patients with ovarian cancer, a recent systematic review and meta-analysis is lacking. The objective of this study was to determine the association of ctDNA with progression-free-survival and overall survival in patients with epithelial ovarian cancer. Methods: An electronic search was conducted using PubMed (MEDLINE), Embase, CENTRAL (Cochrane Library), and CINAHL-Complete from January 2000 to September 15, 2023. To be included in the analysis the studies had to meet the following pre-specified inclusion criteria: (1) evaluable ctDNA; (2) progression-free-survival and overall survival reported as hazard ratio (HR); and (3) the patient population had epithelial ovarian cancer at the time of ctDNA detection. We evaluated the association of ctDNA with progression-free survival and overall survival. Secondary outcomes focused on sub-group analysis of genomic alterations and international Federation of Gynecology and Obstetrics (FIGO) stage. Results: A total of 26 studies reporting on 1696 patients with epithelial ovarian cancer were included. The overall concordance rate between plasma-based and tissue-based analyses was approximately 62%. We found that a high level of ctDNA in epithelial ovarian cancer was associated with worse progression-free survival (HR 5.31, 95% CI 2.14 to 13.17, p<0.001) and overall survival (HR 2.98, 95% CI 1.86 to 4.76, p<0.0001). The sub-group analysis showed a greater than threefold increase in the risk of relapse in patients with positive HOXA9 meth-ctDNA (HR 3.84, 95% CI 1.57 to 9.41, p=0.003). Conclusions: ctDNA was significantly associated with worse progression-free survival and overall survival in patients with epithelial ovarian cancer. Further prospective studies are needed. Prospero Registration Number: CRD42023469390. Competing Interests: Competing interests: CN: travel support from AZ, Illumina. Sponsored talks from Veeva, Illumina, MDS, AZ. (© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu